CRVS

14.09

2.56% -0.37

Dopo l'orario di chiusura: 14.04 -0.05 -0.35%

Corvus Pharmaceuticals Inc (CRVS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$14.46

Aprire:

$14.37

Volume 24 ore:

512.06K

Relative Volume:

0.41

Capitalizzazione di mercato:

$1.19B

Reddito:

Utile/perdita netta:

$-44.17M

Rapporto P/E:

-26.79

EPS:

-0.526

Flusso di cassa netto:

$-35.14M

1 W Prestazione:

-5.50%

1M Prestazione:

+7.80%

6M Prestazione:

-20.93%

1 anno Prestazione:

+153.87%

Intervallo 1D:

$13.79

$14.37

Intervallo di 1 settimana:

$13.79

$15.72

Portata 52W:

$5.28

$26.95

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Nome

Corvus Pharmaceuticals Inc

Settore

Healthcare (1033)

Industria

Biotechnology (582)

Telefono

(650) 900-4520

Indirizzo

901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

CRVS's Discussions on Twitter

Compare CRVS vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRVS Corvus Pharmaceuticals Inc	14.09	1.21B	0	-44.17M	-35.14M	-0.526
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-17	Iniziato	Goldman	Buy
2025-10-13	Iniziato	Barclays	Overweight
2025-01-02	Iniziato	H.C. Wainwright	Buy
2023-08-18	Iniziato	Oppenheimer	Outperform
2021-12-01	Ripresa	Jefferies	Buy
2021-05-27	Iniziato	Cantor Fitzgerald	Overweight
2021-02-10	Downgrade	Mizuho	Buy → Neutral
2019-09-12	Iniziato	Mizuho	Buy
2019-05-29	Iniziato	ROTH Capital	Buy
2017-08-24	Aggiornamento	Credit Suisse	Underperform → Neutral
2017-05-01	Downgrade	Credit Suisse	Neutral → Underperform
2016-04-18	Iniziato	Credit Suisse	Outperform
2016-04-18	Iniziato	Guggenheim	Buy

Mostra tutto

Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie

Aug 21, 2026

Blue Owl Capital Holdings LP Takes Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat

Aug 21, 2026

Aug 20, 2026

Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)? - simplywall.st

Aug 20, 2026

637,500 Shares in Corvus Pharmaceuticals, Inc. $CRVS Bought by DCF Advisers LLC - MarketBeat

Aug 20, 2026

Aug 19, 2026

Corvus (CRVS) Q2 2026 Results: The EPS Result Is Below Expectation; Market Response: The Stock Records a 3.84% Increase in the Current UpdateFinancial Health Score - Vinanet

Aug 19, 2026

Aug 17, 2026

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting - Yahoo Finance

Aug 17, 2026

Aug 16, 2026

Corvus Pharmaceuticals (CRVS) Reports A Wider Loss, Is The Stock Still Cheap? - Sahm

Aug 16, 2026

Aug 15, 2026

CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits

Aug 15, 2026

Aug 14, 2026

Corvus Pharmaceuticals Stock Price Forecast. Should You Buy CRVS? - StockInvest.us

Aug 14, 2026

Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat

Aug 14, 2026

Aug 12, 2026

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail

Aug 12, 2026

Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value (NASDAQ:CRVS) - Seeking Alpha

Aug 12, 2026

HC Wainwright Issues Negative Estimate for CRVS Earnings - MarketBeat

Aug 12, 2026

Aug 11, 2026

Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo

Aug 11, 2026

HC Wainwright Brokers Decrease Earnings Estimates for CRVS - MarketBeat

Aug 11, 2026

The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat

Aug 11, 2026

Aug 10, 2026

H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27 - Moomoo

Aug 10, 2026

Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement - Seeking Alpha

Aug 10, 2026

Aug 09, 2026

Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss? - Sahm

Aug 09, 2026

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Aug 09, 2026

Aug 08, 2026

Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer - The Globe and Mail

Aug 08, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat

Aug 08, 2026

Aug 07, 2026

Corvus Pharmaceuticals Loss Widens to $18 Million as Soquelitinib Trial Costs Soar - finance.biggo.com

Aug 07, 2026

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss - MarketBeat

Aug 07, 2026

State Street Corporation (NYSE: STT) discloses 5.3% ownership in Corvus Pharmaceuticals - Stock Titan

Aug 07, 2026